A. M. Dalsgaard

Most-cited papers

1. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

   T. Guren, M. Thomsen, E. Kure, H. Sørbye +9 more

   2017British Journal of Cancer66 citations Open access

   Semantic Scholar

   Save

2. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas

   V. Sandhu, I. Lothe, K. Labori, O. Lingjærde +9 more

   2015Molecular Oncology45 citations Open access

   Semantic Scholar

   Save

3. The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

   V. Sandhu, D. Wedge, I. B. Bowitz Lothe, K. Labori +12 more

   2016Cancer Research37 citations Open access

   Semantic Scholar

   Save

4. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

   J. B. Kjersem, E. Skovlund, T. Ikdahl, T. Guren +6 more

   2014BMC Cancer36 citations Open access

   Semantic Scholar

   Save

5. Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma

   V. Sandhu, I. B. Bowitz Lothe, K. Labori, M. L. Skrede +10 more

   2016Molecular Oncology20 citations Open access

   Semantic Scholar

   Save

6. Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial

   H. Horndalsveen, T. Alver, A. M. Dalsgaard, L. Rogg +8 more

   2022Molecular Oncology18 citations Open access

   Semantic Scholar

   Save

7. Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome

   L. Silwal-Pandit, S. M. Stålberg, H. Johansson, G. Mermelekas +10 more

   2022Cancer Research Communications8 citations Open access

   Semantic Scholar

   Save

8. Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab

   H. Horndalsveen, V. Haakensen, T. Madebo, B. Grønberg +17 more

   2025Frontiers in Oncology3 citations Open access

   Semantic Scholar

   Save

9. 149P Circulating tumor DNA versus tissue profiling for therapy selection in advanced cancer: Results from the IMPRESS-Norway trial

   I. Dyvik, L. Silwal-Pandit, D. Vodak, I. R. Bergheim +16 more

   2025Annals of Oncology0 citations Open access

   Semantic Scholar

   Save

10. 2977P Dual-time-point [18F] FDG PET/CT and tumour microenvironment features in pleural mesothelioma patients receiving immunotherapy

    S. Thunold, M. Rakaee, K. Giannikou, E. Hernes +7 more

    2025Annals of Oncology0 citations

    Semantic Scholar

    Save

11. 1145P Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: The ComIT-1 trial

    H. Horndalsveen, T. Alver, A. M. Dalsgaard, Å. Öjlert +3 more

    2022Annals of Oncology0 citations Open access

    Semantic Scholar

    Save

12. The cellular proteome of pancreatic ductal adenocarcinoma

    L. Silwal-Pandit, Henrik Johansson, S. M. Stålberg, G. Mermelekas +9 more

    2019Pancreatology (Print)0 citations

    Semantic Scholar

    Save

13. Author's response to reviews Title:FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with 1st line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab Authors:

    J. B. Kjersem, Eva Skovlund, T. Ikdahl, C. Kersten +5 more

    20140 citations

    Semantic Scholar

    Save